ClinicalTrials.gg
Active, not recruitingNCT05668988Updated Oct 29, 2026

A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)

A Phase 3 interventional study of sunvozertinib and Pemetrexed+carboplatin in Non-small Cell Lung Cancer, sponsored by Dizal Pharmaceuticals. Active, not recruiting at 154 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Dizal Pharmaceuticals · Phase 3, Interventional, and Treatment

Updated Oct 29, 20262 sites added6 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
324
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing sunvozertinib in Carcinoma, Non-Small-Cell Lung — 8 open to participants now, 12 under way, 2 of them phase 3. sunvozertinib · Carcinoma, Non-Small-Cell Lung.

Enrollment
2nd of 13
324 · median 100
Started
2022
the only one that year
Phase 3
2 of 13
1 open now
Primary completion
2026-01
later than 5 of 11 live
Registered
3rd of 13
by date
Lead sponsor
5 of 13
Dizal Pharmaceuticals

Among the 13 studies testing sunvozertinib in Carcinoma, Non-Small-Cell Lung, this one is the 2nd largest by enrollment, is the only one that started in 2022, is one of 2 in phase 3, reaches primary completion later than 5 of the 11 other live ones, and was the 3rd registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

8 of the 13 studies testing sunvozertinib in Carcinoma, Non-Small-Cell Lung are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About sunvozertinib

sunvozertinib: first FDA approval 2025 (ZEGFROVY). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing sunvozertinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is a phase 3, open-label, randomized, multi-center study assessing the efficacy and safety of DZD9008 versus platinum-based doublet chemotherapy in participants with locally advanced or metastatic NSCLC with EGFR Exon20ins mutation, who are newly diagnosed or have not received prior systemic therapy in advanced stage.

Primary objective of this study is to assess the efficacy of DZD9008 versus platinum-based doublet chemotherapy using by BICR-assessed PFS per RECIST 1.1 as primary endpoint. Approximately 320 participants are estimated to be randomized into the study. Participants enrolled will be randomized to DZD9008 or platinum-based doublet chemotherapy in a 1:1 manner, stratified by baseline brain metastasis (with/without).

03

Conditions studied

  • Non-small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged at least 18 years old (or per local regulatory/IRB requirement).
  2. or cytologically confirmed diagnosis of non-squamous NSCLC, locally advanced (Stage IIIB and IIIC according to the 8th edition of the AJCC TNM staging criteria) or (Stage IV), not suitable for curative therapy.
  3. Adequate tumor tissue available, for central laboratory confirmation of EGFR exon 20 insertion mutation
  4. At least 1 per Version 1.1
  5. ≥ 12 weeks
  6. (ECOG) performance status of 0 to 1
  7. Adequate organ and hematologic function

Exclusion criteria

Exclusion Criteria:

  1. Prior treatment with any systemic anti-cancer therapy for locally advanced or NSCLC.
  2. Spinal cord compression or .
  3. Concurrent EGFR mutations: exon 19 deletion, L858R, T790M, G719X, S768I, or L861Q.
  4. History of stroke or intracranial hemorrhage within 6 months before randomization.
  5. As judged by the investigator, any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses (i.e., hemophilia and Von Willebrand disease).
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
324 participants (actual)

Study arms

  • Experimental
    sunvozertinib

    Drug: sunvozertinib

  • Active comparator
    Platinum-based Chemotherapy

    Drug: Pemetrexed+carboplatin

Interventions

  • orally, 300 mg, once daily until a treatment discontinuation criterion is met.

  • DrugPemetrexed+carboplatin

    Drug pages: Pemetrexed · Carboplatin

    Participants randomized into chemotherapy arm can receive up to 6 cycles of pemetrexed + carboplatin (pemetrexed 500 mg/m2 + carboplatin area under the plasma concentration-time curve 5 mg/ml per minute (AUC5), IV infusion, every 3 weeks) as the initial treatment. Participants whose disease has not progressed after 4 cycles of first-line platinum-based doublet chemotherapy may receive pemetrexed maintenance monotherapy until a treatment discontinuation criterion is met.

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) as assessed by Blinded Independent Central Review (BICR) per RECIST 1.1

    Time frame: Up to approximately 34 months after the first participant is randomized

Secondary outcomes

  1. Overall Survival

    Time frame: Up to approximately 34 months after the first participant is randomized

07

Study locations

154 sites

Showing the first 100 of 154 sites across 15 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Zhou C, Greillier L, Liu G, John T, Xing L, Kowalski D, Memmott RM, Yazici O, Sun M, Shu C, Pons-Tostivint E, Fan Y, Fernandez-Hinojal G, Shum E, Wang M, Bertolini F, Camidge DR, Zhou C, Doucet L, Hong Q, Fang J, Huang D, Jin B, Yu Y, Antonuzzo L, Moro-Sibilot D, Bennouna J, de Castro G Jr, Zheng L, Heymach JV; WU-KONG28 Investigators. First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations. N Engl J Med. 2026 May 29. doi: 10.1056/NEJMoa2604461. Online ahead of print. PubMed 42212913 ↗
  • Wang M, Fan Y, Sun M, Wang Y, Zhao Y, Jin B, Hu Y, Han Z, Song X, Liu A, Tang K, Ding C, Liang L, Wu L, Gao J, Wang J, Cheng Y, Zhou J, He Y, Dong X, Yao Y, Yu Y, Wang H, Sun S, Huang J, Fang J, Li W, Wang L, Ren X, Zhou C, Hu Y, Zhao D, Yang R, Xu F, Huang Y, Pan Y, Cui J, Xu Y, Yang Z, Shi Y. Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial. Lancet Respir Med. 2024 Mar;12(3):217-224. doi: 10.1016/S2213-2600(23)00379-X. Epub 2023 Dec 12. PubMed 38101437 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2022 to primary completion in Jan 2026, 37 months.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 37 months is close to that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2022
First posted
Dec 30, 2022
StartActual
Dec 13, 2022
Primary completionActual
Jan 16, 2026
CompletionEst.
Oct 31, 2027
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 6 sites removed
Show 2 added (1 United States, 1 China)
  • NYU Langone Health · New York, United States
  • The Affiliated Cancer Hospital of Xinjiang Medical University · Ürümqi, China
Show 6 removed
  • Centro de Educación Médica e Investigaciones Clínicas, CEMIC · Buenos Aires, Argentina
  • Centro Diabaid · Buenos Aires, Argentina
  • Hospital Italiano de Buenos Aires (HIBA) · Buenos Aires, Argentina
  • Instituto Alexander Fleming · Buenos Aires, Argentina
  • Centro de Investigación Clínicas. Clinica Viedma S.A · Viedma, Argentina
  • The Affiliated Cancer Hospital of Xinjiang Medical University · Ürümqi, China
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    2 sites added, 6 sites removed
    Show 2 added (1 United States, 1 China)
    • NYU Langone Health · New York, United States
    • The Affiliated Cancer Hospital of Xinjiang Medical University · Ürümqi, China
    Show 6 removed
    • Centro de Educación Médica e Investigaciones Clínicas, CEMIC · Buenos Aires, Argentina
    • Centro Diabaid · Buenos Aires, Argentina
    • Hospital Italiano de Buenos Aires (HIBA) · Buenos Aires, Argentina
    • Instituto Alexander Fleming · Buenos Aires, Argentina
    • Centro de Investigación Clínicas. Clinica Viedma S.A · Viedma, Argentina
    • The Affiliated Cancer Hospital of Xinjiang Medical University · Ürümqi, China

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05668988
Responsible party
Sponsor
First posted
Dec 30, 2022
Start date
Dec 13, 2022
Primary completion
Jan 16, 2026
Completion
Oct 31, 2027 (estimated)
Last update
Oct 29, 2026

Study contacts

Caicun Zhou
principal investigator · Shanghai Pulmonary Hospital, Shanghai, China

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sunvozertinib

Start the discussion